Absci (NASDAQ:ABSI) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Key Points

• Needham raised its price target on Absci from $11 to $15 and maintained a Buy rating, implying 64.11% upside from the stock’s current price.
• Analyst sentiment is broadly positive: MarketBeat reports a consensus “Moderate Buy” rating and a $15 average price target, with 11 Buy ratings and one Sell rating.
• Absci reported a quarterly loss of $0.19 per share, in line with estimates, while revenue of $0.30 million fell short of the $0.66 million consensus. Investors are also watching for interim ABS-201 hair-loss trial data expected in December 2026.

Absci (NASDAQ:ABSI - Get Free Report) had its price target hoisted by research analysts at Needham & Company LLC from $11.00 to $15.00 in a report issued on Thursday, Benzinga reports. The firm presently has a "buy" rating on the stock. Needham & Company LLC's price target indicates a potential upside of 64.11% from the stock's current price.

Several other brokerages have also recently commented on ABSI. KeyCorp raised their target price on shares of Absci from $16.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, October 16th. BTIG Research reiterated a "buy" rating and set a $16.00 price objective on shares of Absci in a research report on Thursday. Lifesci Capital started coverage on shares of Absci in a research note on Wednesday, September 9th. They set an "outperform" rating on the stock. Wall Street Zen upgraded Absci from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Absci in a research report on Tuesday, October 20th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $15.00.

Absci Price Performance

Shares of ABSI opened at $9.14 on Thursday. Absci has a 12-month low of $2.24 and a 12-month high of $12.54. The stock has a market capitalization of $1.57 billion, a P/E ratio of -11.43 and a beta of 2.22. The firm's 50 day moving average is $9.66 and its 200-day moving average is $6.78.

Absci (NASDAQ:ABSI - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, meeting analysts' consensus estimates of ($0.19). The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.66 million. Absci had a negative return on equity of 61.71% and a negative net margin of 7,756.38%. As a group, equities research analysts forecast that Absci will post -0.76 EPS for the current fiscal year.

Institutional Trading of Absci

Several institutional investors have recently made changes to their positions in ABSI. BlackRock Inc. purchased a new position in Absci during the second quarter valued at approximately $141,112,000. Siren L.L.C. purchased a new stake in Absci in the 1st quarter worth approximately $5,400,000. Parkman Healthcare Partners LLC purchased a new stake in Absci in the 2nd quarter worth approximately $10,366,000. Bank of America Corp DE purchased a new stake in Absci in the 2nd quarter worth approximately $6,560,000. Finally, Artia Global Partners LP acquired a new stake in shares of Absci during the 2nd quarter valued at $5,383,000. 52.05% of the stock is currently owned by institutional investors and hedge funds.

Recent Absci Headlines

These are some of the ABSI headlines that stood out recently:

• Positive Sentiment: Absci said its ABS-201 HEADLINE trial for pattern hair loss remains on track, with 13-week interim proof-of-concept data expected in December 2026 and full 26-week results anticipated in early 2027. Those results are a key near-term catalyst. Article: Absci Q3 2026: December hair-loss data is the only number that matters
• Positive Sentiment: The company had $173.7 million in cash, cash equivalents and marketable securities at quarter-end, which it expects to fund operations into the second half of 2028. It also plans to start a Phase 2 ABS-201 trial for endometriosis in mid-2027. Article: Absci Reports Third-Quarter Results
• Neutral Sentiment: Absci appointed Gerry Muhle, a former executive at Galderma, Allergan and GSK, as chief commercial officer. The hire adds commercialization experience, though its impact will depend on progress in the pipeline. Article: Absci Appoints Gerry Muhle as Chief Commercial Officer

Absci Company Profile

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.